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BACKGROUND: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk of recurrence.
Current guidelines recommend trastuzumab and chemotherapy for most HER-2-positive patients. However, the majority of patients
does not recur and might thus be overtreated with adjuvant systemic therapy. We investigated whether the 70-gene MammaPrint
signature identifies HER-2-positive patients with favourable outcome.
METHODS: In all, 168 T1–3, N0–1, HER-2-positive patients were identified from a pooled database, classified by the 70-gene signature
as good or poor prognosis, and correlated with long-term outcome. A total of 89 of these patients did not receive adjuvant
chemotherapy.
RESULTS: In the group of 89 chemotherapy-naive patients, after a median follow-up of 7.4 years, 35 (39%) distant recurrences and 29
(33%) breast cancer-specific deaths occurred. The 70-gene signature classified 20 (22%) patients as good prognosis, with 10-year
distant disease-free survival (DDFS) of 84%, compared with 69 (78%) poor prognosis patients with 10-year DDFS of 55%. The
estimated hazard ratios (HRs) were 4.5 (95% confidence interval (CI) 1.1–18.7, P¼0.04) and 3.8 (95% CI 0.9–15.8, P¼0.07) for
DDFS and breast cancer-specific survival (BCSS), respectively. In multivariate analysis adjusted for known prognostic factors and
hormonal therapy, HRs were 5.8 (95% CI 1.3–26.7, P¼0.03) and 4.7 (95% CI 1.0–21.7, P¼0.05) for DDFS and BCSS, respectively.
INTERPRETATION: The 70-gene prognosis signature is an independent prognostic indicator that identifies a subgroup of HER-2-positive
early breast cancer with a favourable long-term outcome.
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Overexpression of HER-2 is observed in 15–25% of invasive breast
cancers, and it is considered a negative prognostic factor. Most
HER-2-positive breast cancer patients are deemed to be at a high
risk of relapse by current treatment guidelines and thus, nearly all
patients are allocated to (neo)adjuvant trastuzumab and chemo-
therapy. According to the National Comprehensive Cancer
Network (2009) practise guidelines in oncology, chemotherapy
and trastuzumab are advised for all HER-2-positive lymph node-
positive tumours and all HER-2-positive node-negative tumours
larger than 1cm. Even for moderately or poorly differentiated
tumours 0.6–1cm, this combined treatment should be considered.
For hormone receptor-negative HER-2-positive tumours, the
indication for chemotherapy with or without trastuzumab is
expanded further to include tumours smaller than 0.5cm, if lymph
node micrometastases are present. Endocrine therapy should also
be given in patients with hormonal receptor-positive disease.
The St. Gallen International consensus conference 2007 considered
all patients with HER-2 overexpression at least as intermediate
risk, regardless of tumour size, nodal status or other clinical risk
factors. Nevertheless, it was stated that trastuzumab ‘should not be
viewed as standard treatment in women with a primary tumour
o1cm of size and with no axillary involvement, particularly in
patients with highly and perhaps also incompletely endocrine
responsive disease’ (Goldhirsch et al, 2007, 2009).
Trastuzumab is expensive, requires prolonged course of
treatment and carries a small but potentially serious risk of
cardiac toxicity that can result in permanent disability. The
aggregate data from the adjuvant trastuzumab trials indicate that
the majority of patients with HER-2-positive disease remain
disease-free even in the absence of trastuzumab therapy. This
proportion was 74% (1377 out of 1698) at 3 years follow-up in the
HERA trial (HERceptin adjuvant; Untch et al, 2008). In addition,
analysis of molecular subtypes of breast cancer demonstrated a
B40% relapse-free survival rate in node-negative, HER-2-positive
patients who had not received any systemic therapy at all, with a
median follow-up time of 9 years (Parker et al, 2009). The
identification of a good prognosis subgroup of HER-2-positive
patients, for whom chemotherapy and/or trastuzumab could safely
be omitted, might reduce both unnecessary toxicity and high
treatment costs. In this study, the 70-gene prognosis signature
Received 27 August 2009; revised 9 August 2010; accepted 25 August
2010; published online 16 November 2010
*Correspondence: Dr L J van ‘t Veer; E-mail: l.vt.veer@nki.nl
Previous presentation: Data were presented in part at the San Antonio
Breast Cancer Symposium, San Antonio, TX, USA, 11–14 December
2008 (abstract 4171)
British Journal of Cancer (2010) 103, 1788–1793
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s(MammaPrint, Agendia Inc., Huntington Beach, CA, USA and
Amsterdam, The Netherlands), which is validated as an indepen-
dent prognostic indicator for node-negative and 1–3 node-positive
disease, regardless of oestrogen receptor (ER) status (van ’t Veer
et al, 2002; van de Vijver et al, 2002; Buyse et al, 2006; Bueno-
de-Mesquita et al, 2008; Mook et al, 2008), was used to explore
whether a subgroup of HER-2-positive breast cancer patients with
a favourable long-term outcome could be distinguished.
MATERIALS AND METHODS
Patient population
A database with individual patient data for 1288 patients with
known HER-2 status, 70-gene prognosis profile testing results,
and long-term outcome was pooled from previous studies
(van de Vijver et al, 2002; Bueno-de-Mesquita et al, 2007, 2008;
Kok et al, 2008; Mook et al, 2008). Tumour grading was performed
according to the Bloom–Richardson method. The ER and PR
status were determined by immunohistochemistry (IHC) and
interpreted as positive if 10% or more of the cells were stained.
Histological grading and hormone receptor status were centrally
determined for each involved study by experienced breast
pathologists.
The study patients were selected from the pooled database
according to the following criteria: unilateral stage pT1–3, N0–1,
M0, HER-2-positive invasive breast carcinoma diagnosed between
1984 and 2006, no neoadjuvant chemotherapy and surgical
treatment with either breast-conserving therapy or mastectomy
with sentinel node biopsy or axillary lymph node dissection. This
was followed by radiotherapy and adjuvant systemic therapy if
indicated by local treatment guidelines, taking into account patient
preference and consent. Detailed inclusion criteria for each of the
previous studies have been previously described. All of the studies
were approved by the responsible institutional review boards (van
de Vijver et al, 2002; Bueno-de-Mesquita et al, 2007, 2008; Kok
et al, 2008; Mook et al, 2008).
Assessment of HER-2
The overexpression of HER-2 was defined as either a 3þ staining
score by IHC or by 2þ score and a positive chromogenic in situ
hybridisation (CISH) assay for gene amplification. The majority of
HER-2-positive cases had been determined either at the European
Institute of Oncology, Milan (9 cases) or at the pathology
department of the Netherlands Cancer Institute (NKI), Amsterdam
(121 cases). However, the rate of discordance between local and
central pathology was 32% (12 out of 38 cases from different local
pathology laboratories). Overall we found a 10% discordance rate
(17 out of 168) between original and confirmation assessment of
HER-2 status. Recently, a very high concordance of 95% regarding
HER-2 assessment between the NKI laboratory and an indepen-
dent College of American Pathologists (CAP)-accredited US
reference laboratory using Food and Drug Administration-
approved procedures and American Society of Clinical Oncology/
CAP guidelines has been demonstrated (Roepman et al, 2009).
Molecular analyses
RNA of the frozen tumour samples was extracted, analysed and
classified by the 70-gene MammaPrint signature as either good
or poor prognosis at the FDA-cleared and CLIA-accredited
Agendia Laboratories as previously described (van ’t Veer et al,
2002; Glas et al, 2006). In all, 5 out of 168 tumour samples (3%)
used for this analysis had been used for the development of the
70-gene signature.
Statistical analyses
Time-to-event analyses using updated and centrally verified
individual patient data were performed using the pooled database
(Microsoft Access; Microsoft, Redmond, WA, USA). End points
considered were distant disease-free survival (DDFS), defined as
time from surgery to any distant metastasis and breast cancer
specific survival (BCSS), defined as time from surgery to breast
cancer-related death. Kaplan–Meier survival plots and log-rank
tests were used to assess differences in DDFS and BCSS of the
70-gene profile good and poor prognosis groups. All P-values are
two-sided and were considered statistically significant if less
than 0.05. The adjusted hazard ratios (HRs) and the corresponding
95% confidence intervals (95% CI) for all reported analyses were
derived from Cox proportional hazards models. Covariates used in
adjusted models included age at diagnosis, tumour size, number of
positive lymph nodes, histological grade, ER and PR status, and
hormonal therapy. All statistical analyses were performed with
SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
Role of the funding source
The Austrian Society of Surgery and Agendia BV provided
unrestricted educational grants for the work of M Knauer, and
were not involved in study design, collection, analysis or
interpretation of data, writing neither of the report nor in the
decision to submit the manuscript.
RESULTS
Detailed tumour and treatment characteristics of the HER-2-
positive study population are shown in Table 1. After a median
follow-up of 65 months (range 4–303), 49 (29%) distant
recurrences and 41 (24%) breast cancer-specific deaths occurred
in the 168 HER-2-positive patients. We focused our analyses on
patients who did not receive adjuvant chemotherapy or trastuzu-
mab to assess the prognostic value of the 70-gene signature in a
more homogeneous group of HER-2-positive patients. In this
group of 89 patients without adjuvant chemotherapy, 36 patients
(40%) received adjuvant endocrine treatment. The 70-gene
prognosis signature classified 20 (22%) patients as good prognosis,
with 10-year distant DDFS of 84%, compared with 69 (78%) poor
prognosis patients with 10-year DDFS of 55%. The estimated HRs
were 4.5 (95% CI 1.1–18.7, P¼0.04) and 3.8 (95% CI 0.9–15.8,
P¼0.07) for DDFS and BCSS, respectively. The corresponding
Kaplan–Meier curves with log rank P-values for DDFS and BCSS
are shown in Figure 1.
The HER-2-positive cases characterised as 70-gene good
prognosis were more likely to have lobular cancers (26 vs 4%,
P¼0.002), and were less likely to be histological grade 3 (21 vs
71%, Po0.001). No other statistically significant differences were
found between the groups regarding the other baseline character-
istics, including age, T-stage, lymph node involvement, ER and PR
status, and type of surgery. Significantly fewer patients received
adjuvant endocrine therapy in the good prognosis group compared
with the poor prognosis group: 16 out of 20 patients (80%)
received no endocrine treatment, whereas in the poor prognosis
group 37 out of 69 (54%) did not receive endocrine therapy
(P¼0.041).
In multivariate analysis, adjusted for known prognostic factors
and endocrine treatment as described above, only the 70-gene
signature and tumour size were independently correlated with
10-year distant metastasis-free and BCSS. Detailed results of the
multivariate analyses are shown in Table 2.
In the more heterogeneously treated group of all 168 patients,
including 79 patients treated with adjuvant chemotherapy or
trastuzumab, the univariate HR for good vs poor prognosis by the
70-gene signature for 10-year DDFS was 4.6 (1.1–19.2, P¼0.034).
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sFor BCSS, the HR was 4.2 (1.0–17.5, P¼0.047). The Kaplan–Meier
survival curves for this group are shown in Figure 2.
An exploratory subgroup analysis was performed according to
the degree of hormonal receptor expression in this group of
patients with HER-2-positive disease. To explore whether expres-
sion of hormonal receptors identified a subgroup of HER-2-
positive/70-gene profile low-risk tumours with a particularly
favourable outcome, we separately analysed the 40 out of 168
patients (24%) with HER-2 overexpression that were highly
endocrine responsive (see Kaplan–Meier curves in Figure 3A).
In all, 21 out of these 40 patients did not receive adjuvant
chemotherapy, shown in Figure 3B. According to the 2007
St. Gallen consensus conference, ‘highly endocrine responsive’
tumours express high levels of both steroid hormone receptors in
a majority of cells (Goldhirsch et al, 2007). For this analysis, IHC
staining of both ER and PR in 50% or more of cells were
considered ‘highly endocrine-responsive’. Within this subgroup,
no distant metastases or breast cancer-specific deaths were
observed in the patients with a 70-gene profile ‘good prognosis’
testing result (11 out of 40; 28%). Figure 3A depicts the survival
curves for the 40 highly endocrine-responsive patients and
Figure 3B shows 10-year DDFS and BCSS for the 21 chemo-
therapy-naive patients within this subgroup.
DISCUSSION
This is the first study to demonstrate the existence of a clinically
significant subgroup of patients with HER-2-positive early breast
Distant disease-free survival Breast cancer-specific survival
Good prognosis
Poor prognosis
Good prognosis
Poor prognosis
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
Log-rank (Mantel–Cox) test Log-rank (Mantel–Cox) test
P-value 0.0170 P-value 0.0523
100
80
60
40
20
0
P
e
r
c
e
n
t
 
s
u
r
v
i
v
a
l
100
80
60
40
20
0
Time in years
02468 1 0
Time in years
02468 1 0
Figure 1 Ten-year distant disease-free survival (left) and breast cancer-specific survival (right) according to the 70-gene signature for the 89 HER-2-
positive patients who did not receive chemotherapy or trastuzumab.
Table 2 Results of the multivariate analysis by Cox proportional hazards
models for 89 HER-2-positive patients without chemotherapy or
trastuzumab
Variable HR 95% CI P-value
DDFS
MammaPrint 5.78 1.25–26.66 0.025
Age 0.99 0.95–1.04 0.697
Tumour size 1.07 1.03–1.12 0.001
Number of positive lymph nodes 1.09 0.70–1.70 0.694
Grade 1/2 vs 3 1.12 0.48–2.65 0.793
ER status 1.41 0.54–3.69 0.483
PR status 0.66 0.26–1.71 0.395
Adjuvant hormonal therapy 0.50 0.14–1.74 0.274
BCSS
MammaPrint 4.70 1.01–21.75 0.048
Age 1.00 0.96–1.05 0.884
Tumour size 1.06 1.02–1.11 0.007
Number of positive lymph nodes 1.09 0.68–1.73 0.727
Grade 1/2 vs 3 1.28 0.52–3.20 0.592
ER status 1.27 0.47–3.41 0.639
PR status 0.66 0.24–1.78 0.409
Adjuvant hormonal therapy 0.36 0.09–1.37 0.133
Abbreviations: BCSS¼breast cancer-specific survival at 10 years; CI¼confidence
interval; DDFS¼distant disease-free survival at 10 years; ER¼oestrogen receptor;
HR¼hazard ratio; PR¼progesterone receptor.
Table 1 Tumour characteristics and adjuvant treatment of patients with
HER-2-positive breast cancer
Characteristic
Patients without
chemotherapy or
trastuzumab (n¼89)
All HER-2-positive
patients (n¼168)
Age
Median (range) 50 (28–79) 49 (28–79)
Tumour size
T1 46 (52%) 89 (53%)
T2/3 43 (48%) 79 (47%)
Lymph node status
N0 55 (62%) 96 (57%)
N1 34 (38%) 73 (43%)
Histological grade
Grade 1/2 35 (39%) 64 (38%)
Grade 3 53 (60%) 104 (62%)
ER status
Positive 57 (64%) 103 (61%)
Negative 32 (36%) 64 (38%)
PR status
Positive 36 (40%) 70 (42%)
Negative 53 (60%) 98 (58%)
Adjuvant treatment
Untreated 53 (60%) 53 (32%)
Hormonal therapy 36 (40%) 66 (39%)
Chemotherapy 0 77 (46%)
Trastuzumab 0 25 (15%)
Abbreviations: ER¼oestrogen receptor; n¼number of patients; PR¼progesterone
receptor.
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scancer, who experience a favourable long-term outcome that
can be identified with a validated and commercially available
gene expression assay. The 70-gene MammaPrint signature was
a strong independent prognostic indicator for patients with
HER-2-positive disease in the absence of adjuvant chemotherapy
and/or trastuzumab. Furthermore, in low-risk and highly
endocrine-responsive tumours, no relapses or cancer-related
deaths were observed in the patients classified as good prognosis
by the genomic assay.
One of the clear strengths of this study is the methodological
approach of a pooled analysis of updated, individual patient data,
which allows for appropriate time-to-event analyses by combining
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Figure 2 Ten-year distant disease-free survival (left) and breast cancer-specific survival (right) according to the 70-gene signature for all 168 HER-2-
positive breast cancer patients.
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Figure 3 (A) Ten-year distant disease-free survival (left) and breast cancer-specific survival (right) according to the 70-gene signature for the 40 patients
with HER-2 positive and highly endocrine-responsive tumours according to the St. Gallen criteria (450% ER positive and 450% PR positive). Out of the 11
low-risk patients, 7 were untreated, 4 received chemotherapy and one of these patients received trastuzumab. (B) Ten-year DDFS (left) and BCSS (right)
for the 21 chemotherapy-naive patients.
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sdata from different series into one study (Clarke and Stewart,
1997). Furthermore, HER-2 status of all patients in the respective
series had been centrally determined or reviewed by experienced
breast cancer pathologists during the study periods. To be deemed
HER-2-positive for this study, tumours demonstrated either
3þ IHC staining or 2þ IHC staining and a positive CISH result.
In the good prognosis group, HER-2 overexpression was con-
firmed for all patients by CISH, regardless of the IHC result.
However, the small number of patients, the limited follow-up time
for some patients and the somewhat heterogeneous group of
patients with or without endocrine therapy constitute the major
limitations of this analysis. The significant differences between the
groups regarding histological grade reflect the differences in the
function of genes represented in the 70-gene signature, that is to
say the proliferation cluster. Furthermore multivariate analyses of
retrospective data cannot account for all potential biases in
treatment selection and these data require confirmation in other
datasets and clinical studies. For instance, this subgroup is
currently being evaluated in the ongoing MINDACT trial. The
trial will prospectively evaluate whether it is acceptable to withhold
chemotherapy in these low-risk patients, and subsequent studies
will be undertaken by the TRANSBIG group and others to further
characterise the differences between the genomic high-risk and
low-risk groups. This will include whole-genome arrays of these
patients, analysis of the phosphoinositide-3-kinase pathway and
additional pathways, and grading of histological specimens for the
degree of lymphocyte infiltration by unbiased breast pathologists.
Alexe et al (2007) used an existing microarray dataset of 286
early breast cancers by Wang et al (2005), available from the
National Center for Biotechnology Information GenBank GEO
database. The authors characterised two HER-2-positive sub-
types based on the in silico analysis of 42 tumour samples
with increased expression of HER-2-related genes, with the low
recurrence subtype being associated with a relative overexpression
of lymphocyte-associated genes and prominent lymphocytic
infiltration on histological analysis of 13 independent tumours,
of which only 10 were available for evaluation. This hypothesis-
generating study by Alexe et al relied on the identification
of HER-2-positive genes by the expression level of genes in the
17q12 amplicon, and the authors did not confirm HER-2 positivity
with traditional measures of HER-2 assessment. The authors stated
that stratification by the 70-gene signature was not able to
discriminate high- and low-risk HER-2 subtypes and therefore,
may not provide any additional prognostic information within the
HER-2-positive subgroup. In comparison, in this analysis of 1288
patients of which 168 were HER-2 positive, we found two clearly
different subtypes of HER-2-positive breast cancer. These subtypes
with good or poor prognosis were distinguished by a validated
assay, which is available in daily practise. These results from
pooled individual patient data and the original 70-gene readouts
are in our opinion more robust compared with both the analysis in
the Alexe paper as well as the recently published in silico meta-
analysis by Desmedt et al (2008). In their study, suboptimal data
normalisation and readout from a different microarray platform
might have contributed to the finding that all prognostic
signatures failed to discriminate good vs poor outcome in the
HER-2-positive cluster. A similar analysis was performed by
Wirapati et al (2008) with several publicly available gene
expression datasets. In both papers HER-2 positivity was
determined by molecular classification of HER-2-associated genes
rather than traditional measures of HER-2 protein overexpression
and/or gene amplification.
Before the advent of expression profiling, Harbeck et al (1999)
and Zemzoum et al (2003) investigated urokinase-type plasmino-
gen activator (uPA), and its inhibitor PAI-1 as prognostic factor
for HER-2-positive breast cancer. The authors showed that
uPA/PAI-1 levels in primary tumour tissue indicated an aggres-
sive course of disease in lymph node-negative breast cancer
independent of HER-2 status. The relationship between tumours
identified as low risk by uPA/PA-1 and the 70-gene profile is
unknown.
The second widely used prognostic tool is the 21-gene
recurrence score (Oncotype DX, Genomic Health Inc., Redwood
City, CA, USA; Paik et al, 2004), which is based on real-time
RT–PCR and uses formalin-fixed, paraffin-embedded tissue, and
is retrospectively validated for ER-positive breast cancer. As the
measurement of the expression of the HER-2 gene itself was
chosen as important contributing factor in this ‘knowledge-driven
approach’, most if not all HER-2-positive tumours are classified as
intermediate or high risk and therefore, this assay is unlikely to
add prognostic information for HER-2-positive disease. Of the 55
HER-2-positive cases identified in the NSABP B-14 trial, 50 had a
high recurrence score (RS) and 5 had an intermediate RS,
respectively, whereas none of the patients was assigned to a low
recurrence score (Paik et al, 2004; S Paik, personal communica-
tion). In comparison, the 70-gene signature was developed using
the ‘data-driven approach’ with unbiased, genome-wide gene
expression. The HER-2 gene itself was not on the list of the 70
priority genes selected solely on the basis of differences in gene
expression levels from intact RNA of frozen tumours. This study
suggests, that a clinically meaningful and larger proportion (22%)
of chemotherapy-untreated HER-2-positive tumours are identified
as low risk by the 70-gene profile, and these patients experience a
favourable long-term outcome. This is especially remarkable, as 13
of 16 ER-positive low-risk patients did not receive endocrine
treatment at the time the original studies have been conducted.
Avoiding overtreatment with chemotherapy and/or trastuzumab
for truly low-risk HER-2-positive patients is an important goal,
taking into account the risk of serious adverse events and the cost
of these treatment regimens. Currently, trastuzumab monotherapy
in the absence of chemotherapy is not regarded as standard of care
for patients with HER-2-positive disease, although many experts at
the St. Gallen consensus conference believed that trastuzumab
alone may be reasonable for a subset of patients with HER-2-
positive disease in the future (Goldhirsch et al, 2007). Our data
raises the intriguing hypothesis that this strategy of anti-HER-2
therapy in combination with endocrine therapy might first be
tested in patients with highly endocrine-responsive HER-2-positive
disease and/or patients with hormonal receptor expression with a
‘good prognosis’ 70-gene profile. Recently, Chia et al (2008)
reported similar findings, as the HER-2-positive, ER-positive
subgroup of T1 cancers had a more favourable outcome with
a 10-year BCSS of 92%, as compared with the HER-2-positive,
ER-negative subgroup with a 10-year BCSS of only 76%.
In summary, our study suggests the existence of a low-risk HER-
2-positive subgroup of patients with favourable outcome, which
can be identified by the 70-gene MammaPrint gene signature. The
results of this study support the evaluation of less intensive
treatment strategies in this low-risk group. Further validation of
this important finding is ongoing in the MINDACT trial, whereby
patients with HER-2-positive disease deemed to be at a high
clinical risk by Adjuvant!Online (Ravdin et al, 2001) with a ‘good
prognosis’ MammaPrint profile may be randomised to receive no
chemotherapy but may be treated with trastuzumab alone at the
discretion of the treating physician.
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